Eric M Desjardins1, Gregory R Steinberg2,3. 1. Division of Endocrinology and Metabolism, Department of Medicine, McMaster University, 1280 Main Street West, Hamilton, Ontario, L8N 3Z5, Canada. 2. Division of Endocrinology and Metabolism, Department of Medicine, McMaster University, 1280 Main Street West, Hamilton, Ontario, L8N 3Z5, Canada. gsteinberg@mcmaster.ca. 3. Department of Biochemistry and Biomedical Sciences, McMaster University, 1280 Main Street West, Hamilton, Ontario, L8N 3Z5, Canada. gsteinberg@mcmaster.ca.
Abstract
PURPOSE OF REVIEW: The global prevalence of type 2 diabetes (T2D) is escalating at alarming rates, demanding the development of additional classes of therapeutics to further reduce the burden of disease. Recent studies have indicated that increasing the metabolic activity of brown and beige adipose tissue may represent a novel means to reduce circulating glucose and lipids in people with T2D. The AMP-activated protein kinase (AMPK) is a cellular energy sensor that has recently been demonstrated to be important in potentially regulating the metabolic activity of brown and beige adipose tissue. The goal of this review is to summarize recent work describing the role of AMPK in brown and beige adipose tissue, focusing on its role in adipogenesis and non-shivering thermogenesis. RECENT FINDINGS: Ablation of AMPK in mouse adipocytes results in cold intolerance, a reduction in non-shivering thermogenesis in brown adipose tissue (BAT), and the development of non-alcoholic fatty liver disease (NAFLD) and insulin resistance; effects associated with a defect in mitochondrial specific autophagy (mitophagy) within BAT. The effects of a β3-adrenergic agonist on the induction of BAT thermogenesis and the browning of white adipose tissue (WAT) are also blunted in mice lacking adipose tissue AMPK. A specific AMPK activator, A-769662, also results in the activation of BAT and the browning of WAT, effects which may involve demethylation of the PR domain containing 16 (Prdm16) promoter region, which is important for BAT development. AMPK plays an important role in the development and maintenance of brown and beige adipose tissue. Adipose tissue AMPK is reduced in people with insulin resistance, consistent with findings that mice lacking adipocyte AMPK develop greater NAFLD and insulin resistance. These data suggest that pharmacologically targeting adipose tissue AMPK may represent a promising strategy to enhance energy expenditure and reduce circulating glucose and lipids, which may be effective for the treatment of NAFLD and T2D.
PURPOSE OF REVIEW: The global prevalence of type 2 diabetes (T2D) is escalating at alarming rates, demanding the development of additional classes of therapeutics to further reduce the burden of disease. Recent studies have indicated that increasing the metabolic activity of brown and beige adipose tissue may represent a novel means to reduce circulating glucose and lipids in people with T2D. The AMP-activated protein kinase (AMPK) is a cellular energy sensor that has recently been demonstrated to be important in potentially regulating the metabolic activity of brown and beige adipose tissue. The goal of this review is to summarize recent work describing the role of AMPK in brown and beige adipose tissue, focusing on its role in adipogenesis and non-shivering thermogenesis. RECENT FINDINGS: Ablation of AMPK in mouse adipocytes results in cold intolerance, a reduction in non-shivering thermogenesis in brown adipose tissue (BAT), and the development of non-alcoholic fatty liver disease (NAFLD) and insulin resistance; effects associated with a defect in mitochondrial specific autophagy (mitophagy) within BAT. The effects of a β3-adrenergic agonist on the induction of BAT thermogenesis and the browning of white adipose tissue (WAT) are also blunted in mice lacking adipose tissue AMPK. A specific AMPK activator, A-769662, also results in the activation of BAT and the browning of WAT, effects which may involve demethylation of the PR domain containing 16 (Prdm16) promoter region, which is important for BAT development. AMPK plays an important role in the development and maintenance of brown and beige adipose tissue. Adipose tissue AMPK is reduced in people with insulin resistance, consistent with findings that mice lacking adipocyte AMPK develop greater NAFLD and insulin resistance. These data suggest that pharmacologically targeting adipose tissue AMPK may represent a promising strategy to enhance energy expenditure and reduce circulating glucose and lipids, which may be effective for the treatment of NAFLD and T2D.
Authors: Qiyuan Yang; Xingwei Liang; Xiaofei Sun; Lupei Zhang; Xing Fu; Carl J Rogers; Anna Berim; Shuming Zhang; Songbo Wang; Bo Wang; Marc Foretz; Benoit Viollet; David R Gang; Buel D Rodgers; Mei-Jun Zhu; Min Du Journal: Cell Metab Date: 2016-09-15 Impact factor: 27.287
Authors: Emily C Cokorinos; Jake Delmore; Allan R Reyes; Bina Albuquerque; Rasmus Kjøbsted; Nicolas O Jørgensen; Jean-Luc Tran; Aditi Jatkar; Katherine Cialdea; Ryan M Esquejo; John Meissen; Matthew F Calabrese; Jason Cordes; Robert Moccia; David Tess; Christopher T Salatto; Timothy M Coskran; Alan C Opsahl; Declan Flynn; Matthew Blatnik; Wenlin Li; Erick Kindt; Marc Foretz; Benoit Viollet; Jessica Ward; Ravi G Kurumbail; Amit S Kalgutkar; Jørgen F P Wojtaszewski; Kimberly O Cameron; Russell A Miller Journal: Cell Metab Date: 2017-05-02 Impact factor: 27.287
Authors: Lawrence Kazak; Edward T Chouchani; Mark P Jedrychowski; Brian K Erickson; Kosaku Shinoda; Paul Cohen; Ramalingam Vetrivelan; Gina Z Lu; Dina Laznik-Bogoslavski; Sebastian C Hasenfuss; Shingo Kajimura; Steve P Gygi; Bruce M Spiegelman Journal: Cell Date: 2015-10-22 Impact factor: 41.582
Authors: Zhongxiao Wan; Jared Root-McCaig; Laura Castellani; Bruce E Kemp; Gregory R Steinberg; David C Wright Journal: Obesity (Silver Spring) Date: 2013-09-20 Impact factor: 5.002
Authors: Jessica M Olsen; Masaaki Sato; Olof S Dallner; Anna L Sandström; Didier F Pisani; Jean-Claude Chambard; Ez-Zoubir Amri; Dana S Hutchinson; Tore Bengtsson Journal: J Cell Biol Date: 2014-11-10 Impact factor: 10.539
Authors: Rasmus Kjøbsted; Janne R Hingst; Joachim Fentz; Marc Foretz; Maria-Nieves Sanz; Christian Pehmøller; Michael Shum; André Marette; Remi Mounier; Jonas T Treebak; Jørgen F P Wojtaszewski; Benoit Viollet; Louise Lantier Journal: FASEB J Date: 2018-01-05 Impact factor: 5.191
Authors: T C Peixoto; C B Pietrobon; I M Bertasso; F A H Caramez; C Calvino; T R Santos; E Oliveira; E G Moura; P C Lisboa Journal: Eur J Nutr Date: 2019-08-05 Impact factor: 5.614